MedTrace Logo

Brief Admission Skane: Replacing General Admission for Individuals With Self-harm and Acute Risk of Suicide

NCT02985047 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2018-08-28

No results posted yet for this study

Summary

The purpose of the study is to test a standardized version of brief admission (BA) through randomized controlled trial (RCT). The main objective is to evaluate if BA can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of Borderline Personality disorder. Participants will be allocated to BA + Treatment as Usual (TAU) or TAU.

Conditions

  • Self-Injurious Behavior
  • Suicidal Ideation
  • Suicide, Attempted
  • Borderline Personality Disorder
  • Emergency Services, Psychiatric

Interventions

OTHER

Brief Admission

Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • Region Skane

    lead OTHER

Principal Investigators

  • Sofie Westling, MD PhD · Region Skåne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2018-06-30
Completion
2018-08-10

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02985047 on ClinicalTrials.gov